- Retatrutide is an investigational drug being studied in registered clinical trials.
- ClinicalTrials.gov records NCT06662383 and NCT07232719 provide study context; a registration record without posted results does not establish an outcome.
- Retatrutide is not presented here as FDA-approved, available through Kind MD, or available as a compounded medication.
- Research headlines should be checked against the registry, the publication, the population, and the endpoint.
Current status
Retatrutide is an investigational drug being studied in registered clinical trials. This page does not present it as FDA-approved, available through Kind MD, or supported by completed outcomes.
The registered trials
TRIUMPH-5 (NCT06662383) and TRIUMPH-8 (NCT07232719) are ClinicalTrials.gov records for retatrutide studies. A registry record can show the study design, eligibility, intervention, sponsor, and status. It is not a peer-reviewed outcome report.
Do not turn a trial title, a press release, or a registry entry into a claim of approval, superiority, availability, or patient benefit. Results require a posted analysis with a defined population, comparator, endpoint, follow-up, and limitations.
What these records cannot prove
- They do not establish FDA approval or routine prescription availability.
- They do not establish that retatrutide is available from Kind MD or a pharmacy network.
- They do not establish completed outcomes when the record has no posted results.
- They do not provide directions for dosing, switching, storage, administration, or symptom management.
Questions for evidence literacy
When you see a retatrutide claim, ask: Is it a registry entry, a peer-reviewed publication, or a company announcement? What population and endpoint were studied? Are results posted? Does the source describe an approved product or an investigational intervention? Those questions help keep research status separate from care decisions.
Kind MD is a telehealth platform that connects eligible patients with licensed healthcare providers who may prescribe compounded semaglutide or tirzepatide when clinically appropriate. That governed company description does not make retatrutide an offering.
Discuss currently available care with a licensed provider.
Retatrutide is not presented as a treatment option on this page.
Take the Free Quiz →